A detailed history of Wells Fargo & Company transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 13,483 shares of TARS stock, worth $630,869. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,483
Previous 11,874 13.55%
Holding current value
$630,869
Previous $431,000 15.08%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.17 - $38.73 $40,498 - $62,316
1,609 Added 13.55%
13,483 $366,000
Q1 2024

May 10, 2024

BUY
$19.61 - $39.22 $39,435 - $78,871
2,011 Added 20.39%
11,874 $431,000
Q4 2023

Feb 09, 2024

BUY
$12.98 - $20.73 $32,956 - $52,633
2,539 Added 34.67%
9,863 $199,000
Q3 2023

Nov 13, 2023

SELL
$14.75 - $24.62 $34,883 - $58,226
-2,365 Reduced 24.41%
7,324 $130,000
Q2 2023

Aug 15, 2023

BUY
$11.57 - $19.63 $65,706 - $111,478
5,679 Added 141.62%
9,689 $175,000
Q1 2023

May 12, 2023

BUY
$11.92 - $16.27 $12,718 - $17,360
1,067 Added 36.26%
4,010 $50,000
Q4 2022

Feb 13, 2023

SELL
$14.12 - $18.72 $2,301 - $3,051
-163 Reduced 5.25%
2,943 $43,000
Q3 2022

Nov 14, 2022

BUY
$14.08 - $18.5 $858 - $1,128
61 Added 2.0%
3,106 $53,000
Q2 2022

Aug 12, 2022

SELL
$11.08 - $19.08 $18,481 - $31,825
-1,668 Reduced 35.39%
3,045 $45,000
Q1 2022

May 16, 2022

SELL
$14.49 - $24.28 $42,615 - $71,407
-2,941 Reduced 38.42%
4,713 $79,000
Q4 2021

Feb 14, 2022

SELL
$21.21 - $29.68 $45,177 - $63,218
-2,130 Reduced 21.77%
7,654 $172,000
Q3 2021

Nov 15, 2021

BUY
$21.45 - $29.22 $209,866 - $285,888
9,784 New
9,784 $210,000
Q2 2021

Aug 16, 2021

SELL
$27.16 - $38.59 $52,717 - $74,903
-1,941 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$27.37 - $47.25 $34,267 - $59,157
-1,252 Reduced 39.21%
1,941 $63,000
Q4 2020

Feb 09, 2021

BUY
$19.17 - $49.62 $61,209 - $158,436
3,193 New
3,193 $132,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.25B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.